Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis

Company Overview

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad portfolio of medicines. Its products include generic and specialty pharmaceuticals, injectable medicines, and branded treatments across a range of therapeutic areas.

The company operates through three principal businesses: Injectables, which supplies hospital and clinical medicines; Generics, which offers off-patent prescription products, primarily in the United States; and Branded, which markets medicines under established brand names across the Middle East and North Africa. Hikma also provides contract manufacturing and other pharmaceutical services in selected markets.

Founded in Jordan in 1978 by Samih Darwazah, Hikma has expanded into an international pharmaceutical group serving patients and healthcare providers in the United States, Europe, the Middle East and North Africa, and other markets. The company is headquartered in London, with manufacturing, research and commercial operations in multiple countries.

Key Stats

• Today's Range: $21.10 to $21.10
• 50-Day Range: $20.37 to $22.28
• 52-Week Range: $16.34 to $25.34
• Volume: N/A
• Average Volume: 1,333 shs
• Market Capitalization: $4.68 billion
• P/E Ratio: N/A
• Dividend Yield: 3.60%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Hikma Pharmaceuticals Stock Analysis - MarketRank™

Hikma Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hikma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Hikma Pharmaceuticals has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.07% of the float of Hikma Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Hikma Pharmaceuticals has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Hikma Pharmaceuticals has recently decreased by 1.13%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Hikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 3.60%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Hikma Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

Hikma Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Hikma Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hikma Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:HKMPF
• Previous Symbol: OTC:HKMPF
• CIK: N/A
• Web: www.hikma.com
• Phone: 442073992760
• Fax: 44-20-7399-2761
• Employees: 9,400
• Year Founded: 1978

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 1.82
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $3.35 billion
• Price / Sales: 1.40
• Cash Flow: $3.34 per share
• Price / Cash Flow: 6.32
• Book Value: $11.74 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 221,890,000
• Free Float: N/A
• Market Cap: $4.68 billion
• Optionable: Not Optionable
• Beta: 0.61